Search

Global Health Watch: Development finance, impact of foreign aid cuts + new PrEP resources to track PrEP access, pricing and the pipeline

Moving the STI Research, Development and Diagnostics Agenda Forward

The global burden of STIs is staggering with more than one million treatable STIs being acquired daily, and new threats like antibiotic-resistant gonorrhea and rising syphilis cases demanding urgent action. Yet funding, research, and political attention lag far behind the need.

PxWire is Out!

This issue provides a range of maps to help orient the field on critical HIV prevention activities: the status of delivering injectable cabotegravir (CAB for PrEP); funders and countries on track for early introduction of injectable lenacapavir (LEN for PrEP); and where new Phase 3 efficacy trials testing MK-8527 as a monthly pill for PrEP are taking place.

PxWire Volume 15, Issue 4

This issue provides a range of maps to help orient the field on critical HIV prevention activities: the status of delivering injectable cabotegravir; funders and countries on track for early introduction of injectable lenacapavir; and where new Phase 3 efficacy trials testing MK-8527 are taking place.

EXPrESSIVE Phase 3 Trials Countries of MK-8527

Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.

Source of Lenacapavir for PrEP Supply to Early Adopter Countries

The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with LEN for PrEP over three years. Supply of LEN is due to begin arriving in countries in late 2025 with service delivery planned to start in early 2026.

Source of Programmatic Cabotegravir for PrEP Supply

The first supplies of CAB for programmatic use (as opposed to use in implementation studies) began to arrive in countries in 2024. Currently, 16 countries are rolling out CAB for programmatic use, with the majority of supply provided by PEPFAR, and some additional quantities procured by the Global Fund.

Beyond Borders

Lenacapavir Implementation Studies

Ongoing and planned implementation studies for the lenacapavir as of October 2025.

Global Health Watch: US CDC layoffs, CIFF funding cuts to NGOs + call for streamlined global health architecture at World Health Summit

The US government shutdown escalated this week as the Administration laid off thousands of workers before chaotically retracting many of these notices. The UK-based Children’s Investment Fund Foundation (CIFF) abruptly cut all funding to US-based NGOs, and world leaders urged a streamlined global health system amid funding cuts.